Shares of Yuhan Corp. and SK Biopharm both posted all-time high of 52 weeks

Reporter Kim Jisun / approved : 2023-08-04 03:00:58
  • -
  • +
  • 인쇄

 

[Alpha Biz=(Chicago) Reporter Kim Jisun] Yuhan Corp. and SK Biopharm posted 52-week highs.

As of 11:30 a.m. on the 3rd, Yuhan Corp. is trading at 72,900 won, up 100 won (0.14%) from the previous day. Stock prices soared to 78,900 won at the beginning of the market, breaking the 52-week high.

At the same time, SK Biopharm is trading at 93,500 won, up 2,500 won (2.75%) from the previous day. SK Biopharm also wrote a new 52-week high of 96,400 won during the day.

Stock market sources say investor sentiment is recovering as supply and demand has improved for pharmaceutical and bio shares, which have been marginalized, although they are growth stocks as secondary battery stocks enter a correction phase.

Yuhan Corporation announced on the 28th of last month that its consolidated operating profit jumped 59.9% to 27.1 billion won in the second quarter of this year. Sales rose 2.6 percent to 495.7 billion won during the same period.

Securities firms are raising their standards for Yuhan Corp., which posted good results in the second quarter. Mirae Asset Securities (KRW 80,000→100,000), NH Investment & Securities (KRW 100,000→110,000), KB Securities (KRW 75,000→88,000), and eBest Investment & Securities (KRW 78,000→88,000) have raised their target prices.

SK Biopharm's target stock price is also rising one after another. Hana Securities (KRW 85,000→KRW 90,000), eBEST Investment & Securities (KRW 100,000→KRW 110,000), and SK Securities (KRW 90,000→KRW 100,000) raised their target prices.

 

 

Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)

주요기사

[Exclusive] Samsung Electronics Passes NVIDIA’s HBM3E 12-High Qualification Test, Secures Supply Deal2025.09.19
Civic Groups File Complaint Against Baemin and Coupang Eats Over Alleged Misleading “One-Person Free Delivery” Promotions2025.09.19
KT Confirms Additional Victims in Unauthorized Micro-Payment Case, Faces Criticism Over Initial Response2025.09.19
KFTC Grants Conditional Approval for Joint Venture Between Shinsegae Group and Alibaba Group2025.09.19
Supreme Court Rules in Favor of NTS on U.S. Unregistered Patent Royalties2025.09.19
뉴스댓글 >

건강이 보이는 대표 K Medical 뉴스

HEADLINE

PHOTO

많이 본 기사